drugset
drugset / Trial / NCT02254057

Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects

NCT02254057 ↗

Phase 1 Completed 47 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess the tolerability of BIBT 986 BS after intravenous infusions of 0.1, 0.3, 1.0, 2.5, 5.0, and 10 mg, to assess the pharmacokinetics of BIBT 986 BS after intravenous infusion and to assess the effect of BIBT 986 BS on blood coagulation parameters

Timeline

Start
2002-07
Primary completion
2002-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBT 986 BS Unknown 0.1 mg Intravenous
Subject BIBT 986 BS Unknown 0.3 mg Intravenous
Subject BIBT 986 BS Unknown 1 mg Intravenous
Subject BIBT 986 BS Unknown 2.5 mg Intravenous
Subject BIBT 986 BS Unknown 5 mg Intravenous
Subject BIBT 986 BS Unknown 10 mg Intravenous

Indications

No indication recorded.